Kodatef (Tafenoquine)

Generic Name

Tafenoquine

Brand Names

Kodatef, Krintafel, Arakoda

FDA approval date: August 20, 2018

Form: Tablet

What is Kodatef (Tafenoquine)?

ARAKODA is indicated for the prophylaxis of malaria in patients aged 18 years and older. ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years and older.

Approved To Treat

Malaria

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

FocaL Mass Drug Administration for Vivax Malaria Elimination (FLAME): a Pragmatic Cluster Randomized Controlled Trial in Peru

Enrollment Status: Recruiting

Publish Date: September 08, 2025

Intervention Type: Drug

Study Phase: Phase 3

Summary: FLAME is an open-label cluster-randomized controlled trial that aims to determine the effectiveness of focal mass drug administration (fMDA) to reduce the incidence of Plasmodium vivax malaria in the Loreto Department in Peru. Standard interventions, including symptomatic and asymptomatic screening for malaria infections, provision of insecticide-treated bednets, and environmental transmission mon...

A Randomized, Open-label, Multi-center, Interventional Phase 3 Study of the Efficacy and. Safety of Tafenoquine Compared to Primaquine (Both Co-administered With Chloroquine) for the Radical Cure (Relapse Prevention) of Plasmodium Vivax (P. Vivax) Malaria in Indian Participants (Pediatric and Adult Population)

Enrollment Status: Recruiting

Publish Date: August 07, 2025

Intervention Type: Drug

Study Phase: Phase 3

Summary: The aim of this study is to collect efficacy and safety data to support the registration of tafenoquine in India.

A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria - TAfenoquine DOsing REvised

Enrollment Status: Recruiting

Publish Date: July 18, 2025

Intervention Type: Drug

Study Phase: Phase 3

Summary: The goal of this clinical trial is to assess the efficacy and safety or a revised weight band tafenoquine dose in vivax malaria patients. The main question\[s\] it aims to answer are: * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) non-inferior to high dose primaquine (7mg/kg over 7 days) * is a revised weight-based TQ regimen (TQRevised: target dose 7.5mg/kg) superior to ...

View All Clinical Trials